Next Generation T-cell Vaccine Against Coronavirus Disease (COVID-19)

PHASE1/PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

110

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

June 1, 2026

Study Completion Date

December 1, 2026

Conditions
CoronavirusSARS-CoV-2 InfectionCOVID-19
Interventions
BIOLOGICAL

PepGNP-COVID19 (One vaccination)

One dose with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI

OTHER

Water for injection (One vaccination)

Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose

BIOLOGICAL

PepGNP-COVID19 (Two vaccinations)

Two vaccinations with 7.5 nmol total peptide/dose with 47.8ug gold base particle in 50 µl WFI

OTHER

Water for injection (Two vaccinations)

Water For Injection (WFI): (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) 50 µl per dose

Trial Locations (2)

1229

Tropical Disease Foundation, Makati City

4104

Health Index Multispecialty Clinic, Barangay Toclong 2B, Imus

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Gylden Pharma Ltd

INDUSTRY